Form 4 for RGNX REGENXBIO Inc.
Accepted 2023-12-21 00:00:00 ET · period of report 2023-12-19 · accession 0001562180-23-008519 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2023-12-21 | 2023-12-19 | RGNX | Mills Kenneth T. | Pres, CEO, Dir | M - OptEx | $3.66 | +45.0K | 400.3K | +13% | +$164.8K |
| DT | 2023-12-21 | 2023-12-19 | RGNX | Mills Kenneth T. | Pres, CEO, Dir | S - Sale+OE | $19.69 | -45.0K | 355.3K | -11% | -$886.0K |
| DMT | 2023-12-21 | 2023-12-19 | RGNX | Mills Kenneth T. | Pres, CEO, Dir | M - OptEx | $0.00 | -45.0K | 186.4K | -19% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-19 | M | A | 43,500 | $3.76 | 398,789 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-19 | M | A | 1,500 | $0.85 | 400,289 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-19 | S | D | 45,000 | $19.69 | 355,289 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $19.48 to $20.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Derivative | Stock Options (Right to Buy) | 2023-12-19 | M | D | 1,500 | $0.00 | 36,316 | D | $0.85 · — to 2024-09-24 | 1,500 Common Stock | (F4) The previously granted option, representing a right to purchase a total of 1,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on September 24, 2015, and the balance vested in equal monthly installments over the 36 months thereafter. |
| 5 | Derivative | Stock Options (Right to Buy) | 2023-12-19 | M | D | 43,500 | $0.00 | 186,354 | D | $3.76 · — to 2025-05-19 | 43,500 Common Stock | (F3) The previously granted option, representing a right to purchase a total of 43,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 9, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. |